{"entity":{"id":"nct07487805","kind":"trial","name":"ICONIC: ivermectin combined with immune checkpoint inhibition in cancer (University of Florida phase 2)","aka":[],"tldr":"A University of Florida trial will randomise 80 people already on immunotherapy to two doses of ivermectin and measure a change in their immune cells after two weeks. It is not yet open and does not measure whether tumours shrink.","summary":"ICONIC is a randomised, parallel-arm phase 2 in 80 adults with solid tumours, due to start in September 2026 and reach its primary completion in September 2027 (ClinicalTrials.gov NCT07487805). The primary endpoint is the median fold-change at week 2 in Ki-67-positive, HLA-DR-positive non-naive CD8 T cells, a laboratory marker of T-cell activation, with adverse events and cytokine changes as secondary endpoints (ClinicalTrials.gov NCT07487805). The registry text explains the rationale: widespread off-label use after public claims, a 2023 survey in Loja, Ecuador in which 19 percent of respondents had used ivermectin alongside cancer treatment, virtually absent clinical data, and a reported case of severe neurotoxicity in a patient with metastatic osteosarcoma on regorafenib attributed to a CYP3A4 interaction (ClinicalTrials.gov NCT07487805).","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07487805","url":"https://clinicaltrials.gov/study/NCT07487805"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["checkpoint-inhibitor","drug-repurposing"],"targets":[],"drugs":["ivermectin"],"companies":[],"institutions":["uf-health-cancer-center"],"pathways":[],"terms":["immune-checkpoint","off-label","pharmacokinetics"],"trials":[],"people":[],"bottlenecks":["b-generic-repurposing","b-misinformation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo agent (Claude Fable 5.1)","editedOn":"2026-09-24","note":"Written from cached ClinicalTrials.gov v2, Europe PMC, DailyMed, Drugs@FDA and WHO eEML responses; no figure appears without its source link."},"nct":"NCT07487805","phase":"2","setting":"Adults with solid tumours on a standard immune checkpoint inhibitor: randomised to 200 or 400 micrograms per kg of oral ivermectin on days 1 to 3 of each week for four weeks","sponsor":"University of Florida","result":"Not yet recruiting; no results (ClinicalTrials.gov NCT07487805).","enrolled":80,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07487805/","neighbours":{"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"drug-repurposing","kind":"technology","name":"Systematic drug repurposing","route":"/technologies/drug-repurposing/"}],"drug":[{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/"}],"institution":[{"id":"uf-health-cancer-center","kind":"institution","name":"University of Florida Health Cancer Center","route":"/institutions/uf-health-cancer-center/"}],"term":[{"id":"immune-checkpoint","kind":"term","name":"Immune checkpoint","route":"/terms/immune-checkpoint/"},{"id":"off-label","kind":"term","name":"Off-label","route":"/terms/off-label/"},{"id":"pharmacokinetics","kind":"term","name":"Pharmacokinetics (PK), half-life and exposure","route":"/terms/pharmacokinetics/"}],"bottleneck":[{"id":"b-misinformation","kind":"bottleneck","name":"Misinformation and unproven therapies","route":"/bottlenecks/b-misinformation/"},{"id":"b-generic-repurposing","kind":"bottleneck","name":"No incentive to repurpose cheap drugs","route":"/bottlenecks/b-generic-repurposing/"}],"paper":[{"id":"paper-draganov-ivermectin-cold-tumours-npj-breast-cancer-2021","kind":"paper","name":"Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer (with 2026 expression of concern)","route":"/key-papers/paper-draganov-ivermectin-cold-tumours-npj-breast-cancer-2021/"},{"id":"paper-jimenez-gaona-ivermectin-loja-ecuador-2023","kind":"paper","name":"Outcome of ivermectin in cancer treatment: an experience in Loja, Ecuador","route":"/key-papers/paper-jimenez-gaona-ivermectin-loja-ecuador-2023/"},{"id":"paper-gilene-ivermectin-toxicity-paediatric-oncology-2025","kind":"paper","name":"The threat of medical misinformation: a case of ivermectin toxicity in a pediatric oncology patient","route":"/key-papers/paper-gilene-ivermectin-toxicity-paediatric-oncology-2025/"}]}}